Ariosa Diagnostics, Inc.

Ariosa Diagnostics, Inc. is a biotechnology company specializing in non-invasive prenatal testing solutions, leveraging advanced technologies to enhance maternal-fetal health outcomes. Founded in 2008, Ariosa Diagnostics, Inc. is based in San Jose, US, and focuses on developing innovative prenatal testing solutions.

The company was acquired by Roche in December 2014 for an undisclosed amount. It has engaged in four investment deals, with its most recent funding round being a Series C in December 2014, raising USD 52. 70 mn from investors such as Domain Associates, Meritech Capital Partners, and Venrock. The total amount raised by the company stands at USD 52.

70 mn, with a current valuation of USD 197. 04 mn. Ariosa Diagnostics offers a range of high-quality non-invasive prenatal testing solutions aimed at improving maternal-fetal health. Their flagship product, the Harmony Prenatal Test, utilizes advanced genetic testing technology to provide expectant parents with accurate information about the health of their fetus.

Primarily serving healthcare providers and expecting families, the company’s services are designed to enhance clinical decision-making and support positive pregnancy outcomes. Their geographical reach extends across North America, Europe, and parts of Asia, ensuring diverse access to their testing services. The revenue model of Ariosa Diagnostics is anchored in their laboratory testing services, primarily derived from fees charged for their prenatal testing solutions. The pricing structure ensures that healthcare providers can offer accessible testing options to expecting families.

Revenue is generated through direct sales to healthcare providers, with many clients opting for multiple tests as part of their prenatal care package. This transactional approach reinforces the company’s focus on delivering reliable services tailored to client needs. Ariosa Diagnostics is committed to expanding its product offerings, with plans to enhance its testing solutions and introduce new genetic screening technologies. The company aims to penetrate emerging markets in Asia and Europe by 2025, leveraging its existing infrastructure and strategic partnerships to facilitate growth.

The recent funding round will support these initiatives, enabling the company to invest in research and development for future product launches while optimizing its operational capabilities.